The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The major risk factors for infection in CLL and exploring strategies to mitigate risk
Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the major risk factors for infection in patients with chronic lymphocytic leukemia (CLL), focusing on the hypogammaglobulinemia observed in many patients. A machine learning algorithm is currently being explored to predict which patients are likely to develop an infection, and a short course of acalabrutinib and venetoclax is being investigated to mitigate infections in individuals considered at high risk. Dr Brown also briefly touches on the effect CAR T-cell therapy may have on infection risk. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Loxo/Lilly, Pharmacyclics, Numab Therapeutics, Merck, Grifols Worldwide Operations, Kite, BeiGene, iOnctura, Alloplex Biotherapeutics, Hutchmed, Pfizer, Genentech/Roche, Abbvie, Acerta/AstraZeneca; Research Funding: Loxo/Lilly, TG Therapeutics, Gilead, BeiGene, iOnctura, SecuraBio, MEI Pharma.
